Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
Weiss Ratings | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D+ | |||
Reward Grade | E | |||
Rating Factors | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Good | |||
Volatility Index | Fair | |||
Beta / Standard Deviation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.44 | |||
Price History | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | 6.38% | |||
30-Day Total Return | -7.90% | |||
60-Day Total Return | -1.09% | |||
90-Day Total Return | -11.49% | |||
Year to Date Total Return | -23.33% | |||
1-Year Total Return | 21.59% | |||
2-Year Total Return | 88.35% | |||
3-Year Total Return | 117.73% | |||
5-Year Total Return | 128.39% | |||
52-Week High % Change | -28.38% | |||
52-Week Low % Change | 30.54% | |||
Price | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $22.80 | |||
52-Week Low Price | $12.51 | |||
52-Week Low Price (Date) | Apr 19, 2024 | |||
52-Week High Price (Date) | Dec 26, 2024 | |||
Valuation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 18.71B | |||
Enterprise Value | 33.94B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.46 | |||
Earnings Per Share Growth | 181.76% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 1.12 | |||
Price/Book (Q) | 3.45 | |||
Enterprise Value/Revenue (TTM) | 2.05 | |||
Price | $16.33 | |||
Enterprise Value/EBITDA (TTM) | 7.66 | |||
Enterprise Value/EBIT | 10.06 | |||
Market Cap Category | Large Cap | |||
Dividends and Shares | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 1.13B | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | $0.07 | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | $0.07 | |||
Company Info | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 972 3 914 8213 | |||
Address | -- | |||
Website | www.tevapharm.com | |||
Country | Israel | |||
Year Founded | 1901 | |||
Profitability | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | 20.39% | |||
Profit Margin | -9.90% | |||
Management Effectiveness | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | 5.09% | |||
Return on Equity | -- | |||
Income Statement | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 16.54B | |||
Total Revenue (TTM) | 16.54B | |||
Revenue Per Share | $14.60 | |||
Gross Profit (TTM) | 8.06B | |||
EBITDA (TTM) | 4.43B | |||
EBIT (TTM) | 3.37B | |||
Net Income (TTM) | -1.64B | |||
Net Income Avl. to Common (TTM) | -1.64B | |||
Total Revenue Growth (Q YOY) | -5.12% | |||
Earnings Growth (Q YOY) | -158.89% | |||
EPS Diluted (TTM) | -1.46 | |||
EPS Diluted Growth (Q YOY) | -147.46% | |||
Balance Sheet | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 3.30B | |||
Cash Per Share (Q) | $2.91 | |||
Total Current Assets (Q) | 12.55B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 5.72B | |||
Current Ratio (Q) | 0.981 | |||
Book Value Per Share (Q) | $4.74 | |||
Total Assets (Q) | 39.33B | |||
Total Current Liabilities (Q) | 12.80B | |||
Total Debt (Q) | 18.18B | |||
Total Liabilities (Q) | 33.61B | |||
Total Common Equity (Q) | 5.37B | |||
Cash Flow | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 792.00M | |||
Cash from Financing (TTM) | -1.79B | |||
Net Change in Cash (TTM) | 73.00M | |||
Levered Free Cash Flow (TTM) | 2.61B | |||
Cash from Operations (TTM) | 1.25B | |||